Ursula Eilers

Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN

Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors

Characterization of Alisertib (MLN8237), an Investigational Small-Molecule Inhibitor of Aurora A Kinase Using Novel In Vivo Pharmacodynamic Assays

DNA methylation age of human tissues and cell types

Ubiquitylation of the amino terminus of Myc by SCFβ-TrCP antagonizes SCFFbw7-mediated turnover

MYC on the Path to Cancer

Cell cycle proteins as promising targets in cancer therapy

Role of Oncogenes and Tumor-suppressor Genes in Carcinogenesis: A Review

Metabolic Regulation of Hematopoietic Stem Cells in the Hypoxic Niche

Mammalian display screening of diverse cystine-dense peptides for difficult to drug targets

Myc's other life: stem cells and beyond

Strategies to Inhibit Myc and Their Clinical Applicability

Initial testing of the aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP)

Small Molecule Inhibitors of Aurora-A Induce Proteasomal Degradation of N-Myc in Childhood Neuroblastoma

Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state

Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial

Modeling and Targeting MYC Genes in Childhood Brain Tumors

Stabilization of N-Myc Is a Critical Function of Aurora A in Human Neuroblastoma